Lv21
190 积分 2025-03-25 加入
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
2小时前
待确认
Familial CEBPA-mutated acute myeloid leukemia
15天前
已完结
Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in the Patients with CCAAT Enhancer-Binding Protein a Gene (CEBPA) Mutated Acute Myeloid Leukemia
17天前
已完结
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia
17天前
已完结
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia
17天前
已完结
Pathobiology and Diagnosis of Multiple Myeloma
2个月前
已完结
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
2个月前
已完结
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL
2个月前
已关闭
Gene expression signature of IKZF1 deleted B‐cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4
2个月前
已完结
皖公网安备34019202002308
